Summary & Overview
HCPCS C1721: Implantable Dual-Chamber Cardioverter-Defibrillator
HCPCS Level II code C1721 denotes an implantable dual-chamber cardioverter-defibrillator device used for cardiac rhythm management and delivery of defibrillation and pacing therapies. These devices are critical in preventing sudden cardiac death for patients with high-risk ventricular arrhythmias and for selected patients requiring both atrial and ventricular pacing capabilities. Nationally, implantable cardioverter-defibrillators (ICDs) represent a significant component of advanced cardiac care and capital medical device spending.
This analysis covers coverage and billing considerations for major payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks on payer coverage patterns, common billing modifiers, and clinical context for device use. The content summarizes typical sites of service for implantation and follow-up, highlights where policy updates may affect coding and reimbursement, and outlines the clinical scenarios that commonly justify device implantation.
The publication is intended for revenue cycle leaders, cardiology program directors, and billing professionals seeking a concise reference to HCPCS Level II code C1721, its clinical role, and payer landscape. Data not available in the input is noted where applicable elsewhere in the full publication.
Billing Code Overview
HCPCS Level II code C1721 represents a cardioverter-defibrillator, dual chamber (implantable). This device is used to provide cardiac rhythm management and deliver defibrillation and pacing therapy for patients with life-threatening ventricular arrhythmias and certain bradyarrhythmias.
-
Service type: Implantable cardiac device placement and management
-
Typical site of service: Inpatient hospital or outpatient surgical center for device implantation; device checks and programming typically occur in outpatient cardiology or electrophysiology clinics
Clinical & Coding Specifications
Clinical Context
A typical patient is a 68-year-old male with ischemic cardiomyopathy and symptomatic ventricular tachycardia despite optimal medical therapy, referred for implantation of a dual-chamber implantable cardioverter-defibrillator (C1721). The clinical workflow begins with pre-procedure evaluation: cardiology consult, history and physical, review of recent echocardiogram, assessment of anticoagulation, and informed consent. Pre-procedure testing includes 12-lead ECG, device interrogation if a prior pacemaker exists, basic labs, and chest radiograph as indicated.
On the day of the procedure the patient is admitted to an electrophysiology laboratory or cardiac catheterization suite. Conscious sedation or general anesthesia is administered based on patient factors and anesthesia plan. Vascular access is obtained (typically subclavian or axillary vein), and transvenous leads are advanced into the right atrium and right ventricle with fluoroscopic guidance. The dual-chamber cardioverter-defibrillator generator is implanted in a subcutaneous or submuscular pocket and connected to the atrial and ventricular leads. Lead testing and device programming are performed intraoperatively to confirm appropriate sensing, pacing thresholds, and defibrillation safety testing as clinically indicated. A post-implant chest radiograph confirms lead position; the patient is observed for complications such as hematoma, pneumothorax, or lead dislodgement and receives postoperative device education.
Typical site of service is an electrophysiology laboratory or cardiac catheterization suite within an acute care hospital or an ambulatory surgical center that supports implantable cardiac devices. Length of stay ranges from same-day discharge for uncomplicated implants to overnight observation for higher-risk patients.
Coding Specifications
| Modifier |
|---|